VWA
LYEL icon

VSM Wealth Advisory’s Lyell Immunopharma LYEL Stock Holding History

VSM Wealth Advisory’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250
Closed -$2.21K – 478
2025
Q2 		$2.21K Hold
250
– – ﹤0.01% 469
2025
Q1 		$2.69K Buy
+250
New +$3.06K ﹤0.01% 444

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VSM Wealth Advisory's LYEL Position: Q3 2025 in Review

VSM Wealth Advisory sold out of Lyell Immunopharma (LYEL) in Q3 2025, closing a stake of 250 shares — an estimated $2.21K sold.

VSM Wealth Advisory first reported a position in LYEL in Q1 2025 and held it in 2 quarters. The position peaked at $2.69K in Q1 2025. 59 funds tracked by Wall St. Rank hold LYEL as of Q3 2025.

  • VSM Wealth Advisory reported no remaining Lyell Immunopharma position as of Q3 2025 after selling out during the quarter.
  • VSM Wealth Advisory sold 250 Lyell Immunopharma shares in Q3 2025, an estimated $2.21K.
  • VSM Wealth Advisory first reported a position in Lyell Immunopharma in Q1 2025 and held it in 2 quarters.
  • VSM Wealth Advisory's Lyell Immunopharma position peaked at $2.69K in Q1 2025.
  • 59 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q3 2025.

Based on VSM Wealth Advisory's 13F filing for Q3 2025, filed 13 Nov 2025.